EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer

Xueqin Duan, Xingfa Huo, Yuming Zhang, Hongwei Lan, Fangfang Yang, Xiaochun Zhang, Na Zhou

PeerJ · 2025

DOI: 10.7717/peerj.20251 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PeerJ, 2025. Verfasst von Xueqin Duan und 6 weiteren Autor:innen. Beteiligte Einrichtung: Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China. Hauptthemen laut MEDLINE: Stomach Neoplasms, Transcription Factors, DNA Methylation, DNA-Binding Proteins. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shandong Provincial Natural Science Foundation, Qilu Health Leading Talents Training Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

AT-rich interaction domain 1A (ARID1A), is frequently mutated in cancer, leading to loss-of-function and posing challenges to therapeutic targeting. This study aimed to systematically explore epigenetic regulation of ARID1A, specifically promoter hypermethylation, in gastric cancer (GC) and its functional/immunological consequences.

Methods

We employed multi-omics bioinformatics analyses (UALCAN, cBioPortal, MEXPRESS and UCSC Xena) combined with in vitro functional validation in GC cell lines, including pharmacological demethylation using 5-Aza-2’-deoxycytidine (5-aza-CdR) and mechanistic interrogation via AKT agonism (SC79).

Results

Promoter hypermethylation was identified as a key mechanism silencing ARID1A transcriptional, showing a significant negative correlation between methylation β -values and mRNA expression (Spearman’s ρ = − 0.29, p = 2.06 × 10 −8 ). 5-aza-CdR treatment restored ARID1A expression ( p < 0.001), suppressed malignant phenotypes (proliferation, invasion, and apoptosis resistance), and revealed that ARID1A lose activates the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway (elevated p-AKT, p-mTOR) and upregulates PD-L1. Rescue experiments with SC79 reversed 5-aza-CdR’s effects, confirming the ARID1A-PI3K/AKT/mTOR-PD-L1 axis. Integrative analysis linked ARID1A hypermethylation to elevated immune/ESTIMATE scores ( p < 0.05).

Conclusion

ARID1A promoter hypermethylation drives an epigenetic-immune checkpoint cascade in GC. Combined with its association with immune signatures and PD-L1 upregulation, ARID1A hypermethylation emerges as a candidate biomarker for predicting immune checkpoint blockade (ICB) responsiveness and patient stratification in GC. Future studies should evaluate 5-aza-CdR-ICB-AKT inhibitor regimens in advanced models to guide clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsTranscription FactorsDNA MethylationDNA-Binding ProteinsEpigenesis, GeneticTumor EscapeHumansProto-Oncogene Proteins c-aktB7-H1 AntigenTOR Serine-Threonine KinasesCell Line, TumorGene Expression Regulation, NeoplasticSignal TransductionPromoter Regions, GeneticPhosphatidylinositol 3-Kinases

Stichwörter der Autor:innen

5-Aza-2’-deoxycytidine (5-aza-CdR)ARID1ADNA methylationEpigenetic therapyGastric cancer

Substanzen

ARID1A protein, humanTranscription FactorsProto-Oncogene Proteins c-aktB7-H1 AntigenTOR Serine-Threonine KinasesDNA-Binding ProteinsCD274 protein, humanMTOR protein, humanPhosphatidylinositol 3-Kinases

Autor:innen und Institutionen

  • Precision Medicine Center of Oncology, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China.
  • Department of Medicine, Qingdao University, Qingdao, Shandong, China.
  • Department of Oncology, Qingdao Central Hospital of Health and Rehabilitation University, Qingdao, Shandong, China.

Förderung

  • Shandong Provincial Natural Science Foundation
  • Qilu Health Leading Talents Training Project

Zitieren

APA

Duan, X., Huo, X., Zhang, Y., Lan, H., Yang, F., Zhang, X., & Zhou, N. (2025). Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer. PeerJ. https://doi.org/10.7717/peerj.20251

Vancouver

Duan X, Huo X, Zhang Y, Lan H, Yang F, Zhang X, et al. Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer. PeerJ. 2025. doi:10.7717/peerj.20251

BibTeX
@article{Duan2025,
  author = {Duan, Xueqin and Huo, Xingfa and Zhang, Yuming and Lan, Hongwei and Yang, Fangfang and Zhang, Xiaochun and Zhou, Na},
  title = {Breaking epigenetic shackles: targeting ARID1A methylation and the PI3K/AKT/mTOR-PD-L1 axis to overcome immune escape in gastric cancer},
  journal = {PeerJ},
  year = {2025},
  doi = {10.7717/peerj.20251}
}
Kostenlos starten →